
A recent study investigating the link between diabetes medications and thyroid cancer risk has yielded reassuring results. The research focused on two commonly prescribed drugs for type 2 diabetes: glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors. The study's findings revealed that neither GLP-1RAs nor DPP-4 inhibitors were associated with an increased risk of thyroid cancer compared to SGLT2 inhibitors, another class of diabetes medication. Subgroup analyses and sensitivity analyses further supported these results. This study provides valuable insights, reassuring individuals with type 2 diabetes using these medications.
Like
Save
Share